Bassel F. Shneker, MD
Associate Professor of Neurology
Associate Professor of Pharmacy Practice
Director, Epilepsy Monitoring Unit
Director, Neurophysiology Fellowship - Epilepsy Track
OSU Appointment: 2002
Background: Dr. Shneker received his M.D. Diploma , from University of Damascus, Syria in 1994. He also received a diploma of Qualifying & Specialization in Community Health from University of Damascus, Syria in 1995. He completed his internship in Internal Medicine at Westchester County Medical Center, Valhalla, NY in 1997. In 2000, Dr. Shneker completed his neurology residency at University of Virgina in Charlottesville. That was followed by a 2 year EEG/ Epilespy at University of Virginia which he finished in 2002.
Board Certification:
The American Board of Psychiatry and Neurology (ABPN)
The American Board of Clinical Neurophysiology, INC. (ABCN) (added competency in epilepsy monitoring)
The American Board of Psychiatry and Neurology (ABPN), Certification in Clinical Neurophysiology
Clinical Interests: Intractable Epilepsy, Epilepsy Surgery, Epilepsy Clinical Trials
Research Grants:
Gustavus & Louise Pfeiffer Research Foundation (9/2008-8/2009)
Title: Minimizing the burden of polytherapy antiepileptic drug regimen in patients with intractable epilepsy
Clinical Trials - Bassel F. Shneker, M.D. - click here to expand or contract list
| 9/2008 - ongoing | Protocol E2007-G000-304: A double-blind, placebo-controlled, dose-escalation, parallel-group study to evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures (PI, 2) |
| 7/2008 - ongoing | Protocol A0081047: A double-blind, randomized, multicenter efficacy and safety study of pregabalin (lyrica) as monotherapy in patients with refractory partial seizures (PI, 2) |
| 4/2008 - ongoing | Protocol SP 925: A Multicneter, Open-Label Trial to Assess the Safety and Tolerability of A Single Intravenous Loading Dose Of Lacosamide Followed by Oral Lacosamide Maintenance as Ajdunctive Therapy in Subjects with Partial-Onset Seizures (PI, 8) |
| 4/2008 - ongoing | Protocol SP 926: A Multicneter, Open-Label, Extension Trial to Assess the Long Term Safety and Tolerability of Lacosamide as Ajdunctive Therapy in Subjects with Partial-Onset Seizures (PI, 8) |
| 1/2008 - ongoing | Protocol OV-1012: Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome (PI) |
| 1/2008 - ongoing | Protocol OV-1004: Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastaut Syndrome (PI) 12/2007 – ongoing Protocol 07-001: A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures (PI, 2) 9/2007 – 8/2008 Protocol N01281: An open-label, long-term follow-up study with Keppra XR for treatment of partial-onset seizures (PI, 1) |
| 9/2007 - 8/2008 | Protocol N01280: A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures. (PI, 1) |
| 9/2007 - ongoing | Protocol N01253: An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (greater than or equal to 16 to 70 years old) with Partial Onset Seizures (PI, 5) |
| 8/2007 - ongoing | Progesterone therapy for women with Epilepsy (PI, 1) |
| 5/2007 - ongoing | Protocol 1042-0600: A double-blind, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of ganaxalone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures (PI, 9) |
| 5/2007 - ongoing | Protocol 1042-0601: An open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxalone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures (PI, 9) |
| 2/2007 - ongoing | Protocol 333369-EPY-3001/3004: A randomized, double-blind, placebo-controlled,parallel-group,multicenetr study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study (PI, 5) |
| 11/2006 - ongoing | Protocol E2080-A001-301: A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures (PI, 18) |
| 11/2006 - ongoing | Protocol E2007-A2001-207: A 14 month, open label extension phase of a double blind, placebo-controlled, dose-escalation parallel-group study of E2007 as an adjunctive therapy in patients with refractory partial seizures (PI, 5) |
| 9/2006 - ongoing | Protocol LAM 30055: A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for The Treatment of Partial Seizures. (PI, 10) |
| 3/2006 - ongoing | Protocol K826-05-3001: A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the Efficacy and Safety of Vanquix™ Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures” (PI, 6) |
| 2/2006 - ongoing | Protocol N01199: An open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 100 mg/day in subjects aged 16 years or older suffering from partial onset seizures. (PI, 10) |
| 1/2006- 12/2006 | Protocol N01193: A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, dose-ranging trial evaluating the efficacy and safety of brivaracetam used as adjunctive treatment at doses of 5, 20, and 50 mg/day in b.i.d. administration (oral tablets of 2.5 or 10 mg) for a maximum of 7 weeks in subjects from 16 to 65 years with refractory epilepsy suffering from partial onset seizures whether or secondarily generalized. (PI, 5) |
| 9/2005 - 1/2007 | Protocol N01192: An open-label, exploratory, multicenter, dose escalation study examining the efficacy, safety, and tolerability of UCB 44212 (seletracetam) used at doses of 10mg, 20 mg, 40 mg and 80 mg b.i.d (total doses of 20-160 mg) administration (orally) in adults subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures who are currently receiving levetiracetam (LEV) but still experiencing seizures (PI, 6) |
| 8/2005 - 9/2006 | Protocol E2007- A001-206: Double-blind, placebo-controlled, dose-escalation, parallel-group study of E2007 given as adjunctive therapy in patients with refractory partial seizures (PI, 5) |
| 7/2005 - 2/2007 | Protocol 333369-EPY-2003/2006: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures (PI, 2) |
| 5/2005 - 1/2007 | Protocol N01191: An open-label, exploratory, multicenter, dose escalation study examining the efficacy, safety, and tolerability of UCB 44212 used at doses of 10mg, 20 mg, 40 mg and 80 mg b.i.d in adults subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures and treated with 1,2 or 3 approved antiepileptic drugs. (PI, 10) |
| 6/2004 - ongoing | Protocol IXL-201F-14-189: Talampanel Open-Label Adjunctive Therapy: A Follow-on Study To Determine Long-Term Safety and Efficacy in Patients with Partial Seizures. (PI, 11) |
| 5/2004 – 9/2005 | Protocol LAM 40124: An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy. (PI, 30) |
| 6/2004 – 8/2005 | Protocol IXL-201-14-189: Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients with Partial Seizures: A Phase II Clinical Trial. (PI, 11) |
| 1/2004 – 9/2005 | Protocol 1008-035: Pregabalin BID Open-Label Add on Trial: An Open Label Multicenter Follow-On Study to Determine Long Term Safety and Efficacy in Patients with Partial Seizures. (PI, 5) |
| 5/2004 – 7/2006 | SP 754: Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of SPM927(400 and 600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization (Sub I) |
| 5/2004 – ongoing | SP 756: An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients with Partial Seizures.(Sub I) |
| 8/2002 – ongoing | SPM 927, Protocol SP 615: An Open-label Extension Trial to Determine Tolerability and Efficacy of Long Term Oral SPM 927 as Adjunctive Therapy in Patients with Partial Seizures. (Sub I) |
| 2002 - 9/2005 | Pregabalin Open-Label, Follow-On Safety Trial in Patients with Partial Epilepsy. (Protocol 1008-008). (Sub I) |
| 2002 - 9/2005 | Pregabalin Open-Label Add-On Trial: An Open-label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures. (1008-010). (Sub I) |
| 2003 - 2004 | LAM 40112: Double-blinded Randomized Trial of Cognitive Effects of Lamictal versus Topiramate in Epilepsy (Sub I, 12) |
| 2000 - 2001 | Multi-center, open-label, long-term, follow-up study of the safety and efficacy of ucb LO59 in children with epilepsy (N157). UCB Pharma. |
| 2000 - 2001 | Open-label, follow-on study of pregabalin to determine long-term safety and efficacy in patients with partial seizures (1008-035). Park-Davis. |
| 2000 - 2001 | Open-label extension study of harkoseride as adjunctive therapy in patients with partial seizures (01-202). Harris FRC. |
| 2000 - 2002 | Safety/efficacy of two monotherapy doses of topiramate for newly diagnosed or recurrent epilepsy (106). R.W.Johnson |
| 2000 - 2001 | Double-blinded randomized trial of levetiracetam for intractable partial seizures in children (N159). UCB Pharma |
| 2000 - 2002 | Randomized trial to evaluate the development of polycystic ovarian syndrome in newly diagnosed epilepsy patients initiating lamotrigine vs. valproate (30007). Glaxo Wellcome. |
| 2000 - 2001 | Zonisamide dose titration study (501). Elan. |
| 2000 - 2002 | Double-blinded study of Lamictal for seizures in patients 1-24 months old (20006); extension study (20007). |
| 2001 - 2002 | Maximum tolerated dose study of SPM927 for partial seizures (SP 607). Schwarz Pharma. |
| 2001 - 2001 | Piracetam for cortical myoclonus (N01004). UCB Pharma. |
| 2001 - 2002 | An open-label, multi-center, repeated dose pharmacokinetic study of 20,40, and 60 mg/kg/day of levetiracetam in children (4-12 years of age, inclusive) with refractory partial seizures (N01010). |
| 2002 - 2002 | Double-blinded, randomized controlled trial of SPM 927 for refractory partial-onset seizures (SP617). Schwarz Pharma. |
| 2002 - 2004 | A multi-center, double-blind, randomized, placebo-controlled, parallel group trial to investigate the efficacy and safety of SPM 927 (200 mg/day, 400 mg/day, 600 mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization (SP 667). |
| 2003 - 2004 | A MultiCenter Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms (LAM40117) |
Publications: Pubmed.com list of recent publications by Bassel F. Shneker, M.D.
Appointment Phone: (614) 293-4969
Fax: (614) 293-6111
Address:
395 W. 12th Ave, 7th Floor
Columbus, OH 43210
The Ohio State University